ARCHIVES

XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study

This article is from The Cancer Letter archive.

Vol. 34 No. 3 | March 25, 2011

Download PDF Visit The Full Archive

Related Articles

In Brief: Hammond Resigned As ACS Officer; Wykoff Slated To Direct FDA Special Populations Office

November 20, 1992

Treatment Doesn’t Always Follow Recommendations

February 25, 2005

In Brief; NCAB To Hear Report On Human Cancer Virus, Mayo Projects, Proposed FDA Regulations

February 28, 1975

Porter Novelli Gets $7.4M Contract For 5 A Day Program

October 4, 2002

MD Anderson Expands Reach Into Florida, Ohio

September 26, 2014

NIH Director’s Office Funds $106 Million In Cancer Grants With Stimulus Dollars

September 18, 2009